Opaleye Management Inc. has made headlines with its recent acquisition of shares in Grace Therapeutics, Inc. This move, reported in a filing on October 21, 2026, is significant as it underscores Opaleye's active investment strategy in the pharmaceutical preparations sector.

According to the filing, Opaleye acquired 4,256 shares of Grace Therapeutics at a price of $1.88 per share on October 19, 2026. Following this transaction, Opaleye now holds a total of 2,948,610 shares in Grace Therapeutics. This acquisition not only highlights Opaleye's commitment to expanding its portfolio but also positions it as a key player in the pharmaceutical industry.

Background

Opaleye Management Inc. is based in Boston, Massachusetts, and operates as an investment management firm. The company is known for its strategic investments in various sectors, including pharmaceuticals. Grace Therapeutics, Inc., the company in which Opaleye has increased its stake, is categorized under the pharmaceutical preparations sector, specifically identified by the SIC code 2834.

What the Filing Says

The SEC filing reveals that Opaleye's acquisition was executed through its investment vehicle, Opaleye, L.P. The filing states, "Represents securities owned directly by Opaleye, L.P. (the 'Fund'). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund." Furthermore, Opaleye Management disclaims beneficial ownership of the shares except to the extent of its pecuniary interest.

Impact

This acquisition may have significant implications for both Opaleye Management and Grace Therapeutics. Opaleye's increased ownership stake could influence Grace's strategic decisions and market positioning. Additionally, this move may prompt competitors within the pharmaceutical sector to reassess their strategies, especially in light of Opaleye's growing influence.

What's Next

The filing does not say what happens next regarding Opaleye's investment strategy or any future plans for Grace Therapeutics.